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Abstract
Background: Herpes Simplex Virus 1 and 2 causes several infections in humans including cold sores and
encephalitis. Previous antiviral studies on herpes viruses have focussed on developing nucleoside analogues that
can inhibit viral polymerase and terminate the replicating viral DNA. However, these drugs bear an intrinsic non-
specificity as they can also inhibit cellular polymerase apart from the viral one. The present study is an attempt to
elucidate the action mechanism of naturally occurring withaferin A in inhibiting viral DNA polymerase, thus
providing an evidence for its development as a novel anti-herpetic drug.
Results: Withaferin A was found to bind very similarly to that of the previously reported 4-oxo-DHQ inhibitor.
Withaferin A was observed binding to the residues Gln 617, Gln 618, Asn 815 and Tyr 818, all of which are crucial
to the proper functioning of the polymerase. A comparison of the conformation obtained from docking and the
molecular dynamics simulations shows that substantial changes in the binding conformations have occurred. These
results indicate that the initial receptor-ligand interaction observed after docking can be limited due to the
receptor rigid docking algorithm and that the conformations and interactions observed after simulation runs are
more energetically favoured.
Conclusions: We have performed docking and molecular dynamics simulation studies to elucidate the binding
mechanism of prospective herbal drug withaferin A onto the structure of DNA polymerase of Herpes simplex virus.
Our docking simulations results give high binding affinity of the ligand to the receptor. Long de novo MD
simulations for 10 ns performed allowed us to evaluate the dynamic behaviour of the system studied and
corroborate the docking results, as well as identify key residues in the enzyme-inhibitor interactions. The present
MD simulations support the hypothesis that withaferin A is a potential ligand to target/inhibit DNA polymerase of
the Herpes simplex virus. Results of these studies will also guide the design of selective inhibitors of DNA POL with
high specificity and potent activity in order to strengthen the therapeutic arsenal available today against the
dangerous biological warfare agent represented by Herpes Simplex Virus.
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Herpes Simplex Virus type 1 and type 2 (HSV-1 and
HSV-2) are two members of Herpesviridae family, which
infect almost 85% of the world population [1]. They are
the causative agents of a gamut of diseases ranging from
mild ones like cold sores in mouth, eye cornea and geni-
tals to more severe life threatening ones like the fatal
herpes encephalitis [2]. People with suppressed immune
system like those suffering from AIDS are more prone to
get infections from HSV than others [3].
Drugs for HSV
There is no permanent cure for these infections till date.
Present day treatment involves the use of antiviral drugs
to reduce the physical severity of outbreak-associated
lesions and viral shedding, though this helps decreasing
the chances of transmission to others only by maximum
50% [4]. There are two types of drugs that are clinically
useful against HSV infections. The first category consists
of nucleoside analogs like acyclovir and its prodrug
valacyclovir, ganciclovir, penciclovir and its prodrug
famciclovir, sorivudine and brivudine. These require
phosphorylation by viral thymidine kinase to form
triphosphates that are active inhibitors of viral DNA
polymerase. The second category consists of direct viral
DNA polymerase inhibitors like vidarbine, foscarnet and
cidofovir [5]. Thus, both types of drugs target in dysfunc-
tioning the replication centre i.e. DNA polymerase of the
viral genome [6].
Development of alternative treatments for HSV
However, in past few years, a number of acyclovir drug
resistant viral strains have been isolated especially from
immuno-compromised patients [7-9]. In this era, where
the number of immuno-suppressed patients like those suf-
f e r i n gf r o mH I Vi sc o n t i n u o u s l yi n c r e a s i n g ,t h e r ei sa n
immediate need to find new drugs to treat HSV infections
which have a higher efficacy or have an alternative mode
of action [10]. Resistance to acyclovir is mainly due to
mutations in the viral thymidine kinase (TK) gene which
impair the initial drug phosphorylation [11]. These drug
resistant strains have been of significant clinical attention
[12,13], indicating the need for alternative anti- HSV
drugs. Previous antiviral studies on herpes viruses have
focussed on developing nucleoside analogues that will
inhibit viral polymerase and terminate the replicating viral
DNA. A number of new anti-viral drugs against HSV
DNA polymerase are currently under research and devel-
opment; these focus other domains of the polymerase
than those targeted by the commercially available drugs
[14]. One such novel class of compounds is that of 4-oxo-
DHQs belonging to the non-nucleoside anti-herpetic
drugs family [15].
Traditional medicines
Medicinal plants products have been used over cen-
turies as traditional remedies for different kinds of
diseases including viral diseases. Recently, there have
been studies which report anti-viral activities of
extracts from plants like Swertia chirata, Aloe forex
and Withania somnifera against HSV [16,17]. These
plant extracts inhibit the formation of HSV-1 plaque
above a certain minimum concentration and their
activities can be compared to the commercial drugs
like acyclovir.
Withania somnifera or Winter Cherry or Indian gin-
seng is a proud herb of Ayurveda, classified as Rasayan
(the most esteemed of Ayurveda herbs) [18]. It is held in
high repute in traditional Indian medicine mainly
because of its constituents called withanolides [19]. They
are built on an ergostane framework, which is oxidized at
C-22 and C-26 to form a six-member lactone ring. With-
aferin A (WA), the first withanolide to be isolated and
the major withanolide present in Indian variety of plants
has been widely researched for its pharamacological
activities including anti-inflammatory, anti-cancer, anti-
stress and immunomodulatory, adaptogenic, central
nervous system, endocrine and cardiovascular activities
[20-25]. Leaves of Withania somnifera have been
reported to have the highest content of WA (around
0.001 to 0.5% dry weight of leaves) [26].
In this study, we report a possible mode of action of
withaferin A against HSV by inhibition of its DNA poly-
merase. Molecular docking studies have been used to
identify the binding modes. Dynamic structural patterns
were studied using Molecular dynamics simulations.
Methods
Ligand and receptors
The crystal structure of HSV DNA polymerase [PDB:
2GV9] was obtained from the Protein Data Bank (PDB)
[27]. The structure of this enzyme has been described else-
where [15]. This structure was then subjected to certain
modifications which would make it suitable for docking as
described elsewhere [28]. The structure of the ligand
molecule withaferin A [PubChem:265237] retrieved from
NCBI-PubChem Compound database [29] is shown in
Figure 1. Amber 11 [30], was used to minimise the energy
of the ligand and the receptor using Steepest Descent and
Conjugate Gradient Methods.
Semi-flexible docking
Semi-flexible molecular docking of the HSV DNA poly-
merase along with ligand WA was implemented using
AutoDock 4.0 [31]. The general procedure for perform-
ing docking is described elsewhere [28]. The outputs
from AutoDock were rendered with PyMOL [32] and
Grover et al. BMC Bioinformatics 2011, 12(Suppl 13):S22
http://www.biomedcentral.com/1471-2105/12/S13/S22
Page 2 of 9Accelerys ViewerLite 5.0. Confirmation of the results
were achieved using ParDOCK [33].
MD simulations in water
The energy minimization and MD simulations of HSV
POL and its complex with WA were carried out using
AMBER package as fully described elsewhere by the
authors [28].
Results and discussion
Docking of withaferin A into HSV POL
We performed docking of WA into X-Ray crystal struc-
ture of HSV POL. Using binding pocket analysis, a cavity
around the active site/subsites of HSV POL was pre-
dicted where WA was found binding to the critical active
site residues of HSV POL with a binding energy of -8.46
Kcal/mol. The ligand formed several H-bond interactions
with the crucial residues of the polymerase (Figure 2A).
Ring amino hydrogen of His 765 formed bond with term-
inal hydroxyl group of WA. The same hydroxyl of WA
bonded up with amino group of Asn 755 also. The other
terminal hydroxyl of WA also interacted with side chain
carbonyl of Gln 618. Gln 618 is one of the active site resi-
dues of HSV POL, being a part of the hydrophobic
pocket. Apart from H-bonds, WA was also found form-
ing hydrophobic interactions. As shown in Figure 2B,
WA formed van der waals interactions with the highly
conserved residues Tyr 662 and Tyr 758, which lie in
close proximity to the catalytic site. The properties of the
docked ligand are shown in Table 1.
MD simulations in water
Since molecular docking provides only a static view of
the protein-ligand interactions, we performed molecular
dynamics simulations on HSV POL in complex with
WA to study the interactions in motion. The overall
goal of these simulation steps was to account for protein
flexibility and movement that however could not be
achieved in the docking simulations alone. Figure 3A
shows the H-bond interactions of the docked WA with
HSV POL in a 10 ns simulated snapshot. WA was
found forming H-bond interactions with Gln 617, Phe
718, Asn 815 and Asp 888 of HSV POL. Strong hydro-
phobic interactions by the residues Phe 718, Pro 723,
Tyr 722 and Tyr 818 of HSV POL were also observed in
this simulated structure (Figure 3B).
To probe the dynamic flexibility changes in the pro-
tein, due to the inhibitor binding in its critical regions,
B-factors (Bn)f o rt h eC a atoms were calculated using
the following relation:
Bn = 8/3 π rn
2
where rn is the root-mean-square atomic fluctuation of
the Ca atom of residue n. As shown in Figure 4A, the
calculated Bn values for the undocked protein show a
major peak for the residues 615-625 close to the active
site that possibly determines its function through large-
amplitude motion. However, on docking with WA, a
decrease in Bn values of the protein was observed that
shows its conformational rigidity. Further, this points out
that the large-amplitude motion of the flexible residues
615-625, which encompasses two consecutive catalyti-
cally-active glutamines 617 and 618, is retarded by the
binding of WA to active site of HSV POL. This suggests
the inhibitory activity of WA against HSV POL, as in our
docked structures WA established hydrogen bonds with
these residues. In another instance, for the region 800-
850 in which most of the catalytic site residues are
located, Bn values for WA bound polymerase were seen
attenuated in comparison to those of the enzyme alone.
The RMSDs for the trajectory of WA bound HSV POL
reveals the stability of the complex (Figure 4B). The
RMSD of the complex has achieved a stationary phase
during the later stage of the simulation and is always less
than 3.0 Å for the entire simulation length. The thermo-
dynamic stability of the complex was evident as the
Figure 1 Structures of withanolides. (A) Withaferin A falls under
the family of naturally occurring C28- steroidal lactones known as
withanolides. (B) Structure of withaferin A.
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than that of the protein (red) throughout the simulation
(Figure 4C).
Analysis of pre- and post-MD simulated structures
From the interactions shown in Figure 5A and 5B as
Ligplots [34], a significant difference in the number and
nature of interactions was observed. The binding energy
based on the physico-chemical properties of the active
Figure 2 Interactions of docked withaferin A with HSV POL before MD. (A) H-Bond interactions of the docked ligand with the polymerase
residues. (B) Docked withaferin A forming van der waals interactions with the hydrophobic residues of HSV POL.
Table 1 Properties of the docked conformation
Ligand withaferin A
Docked using AutoDock
Binding energy -8.46 Kcal/mol
Ligand efficiency -0.25
Inhibition constant 624.75 nM
Intermolecular energy -9.03 Kcal/mol
Total internal energy -0.8 Kcal/mol
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and -8.84 Kcal/mol for the post- and pre-MD simulated
structures respectively. The comparative parametric
values of the two structures calculated using RASPD
server [33] are shown n Table 2. Close visual inspection
of the MD results permitted us to observe that post-MD,
WA was able to establish a better structurally stable con-
formation. As evident from Figure 5C, in the pre-MD
Figure 3 Interactions of docked withaferin A with HSV POL post-MD. (A) H-Bond interactions of the docked ligand with the polymerase
residues. (B) Docked withaferin A forming van der waals interactions with the hydrophobic residues of HSV POL.
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tail inside the cavity of HSV POL. On the other hand, the
behaviour of WA was much more stable in the post-MD
simulated structure where its tail is well anchored inside
the deep narrow gorge of the polymerase. Moreover, the
ligand substantially moved towards the residues of HSV
POL to form additional H-bonds. The residues Phe 718
and Asp 888 with which WA established H-bonds in the
Figure 4 (A) Plot of B-factor values of HSV POL (red) and WA/HSV POL (blue). (B) Plot of root mean square deviation (RMSD) of Ca of HSV POL
(protein) and WA/HSV POL (complex). (C) Plot of total energy of HSV POL (protein) and WA/HSV POL (complex).
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nation essential for the catalysis of polymerase. Another
WA H-bonding residue Asn 815 of HSV POL, is a highly
conserved residue which besets on the prolonged second
a helix of the finger domain. The continuous nature of
this structure is responsible for bringing the other highly
conserved residues Tyr 818 and Gly 819 into close proxi-
mity of the catalytic site for facilitating proper function-
ing of the polymerase [15]. In the post-MD simulated
structure, the intensity of hydrophobic interactions
was also found enhanced as compared to those present
before MD. The residues Phe 718, Tyr 722, Pro 723 and
Tyr 818 provided significant hydrophobic contacts for
stabilization of WA inside the cavity. The ribose of the
incoming nucleotide has been earlier report to interact
with the conserved Tyr 722 residue and induces a steric
access effect against inclusion of the nucleotides [15].
Non-nucleosidic inhibition of HSV POL by WA
It has been earlier reported that 4-oxo-dihydroquinolines
(4-oxo-DHQs) have shown broad anti-HSV activity
[35,36]. This class of compounds inhibit most human
herpes viruses, which is associated with DNA polymerase
inhibition. From the binding assays of PNU-183792 , a
r a d i o l a b e l l e dD H Qo nH S VP O L ,i tw a so b s e r v e dt h a t
this inhibitor binds only to HSV POL in complex with
the DNA duplex; while no binding was observed either
with HSV POL or with DNA duplex alone [15]. However,
i no u rc a s ew eo b s e r v e dt h a tW Ai sa b l et ob i n dt ot h e
segregated HSV POL itself. From visual inspection of the
structures of WA and the 4-oxo-DHQ inhibitor, it was
observed that both these ligands contain 2 ketonic
groups, an oxygen containing heterocyclic ring and a tail
containing an electronegative atom. In the present study,
the binding mode of WA was found similar to that of the
radiolabelled 4-oxo-DHQ in which the residues Gln 617,
Gln 618, Asn 815 and Tyr 818 play critical role in the
stabilization of the ligand. It can be deduced from our
Figure 5 Comparative analysis of pre- and post-MD simulated structures. (A) Ligplot of pre-MD structure (B) Ligplot of post-MD
structure (C) Structural alignment of the ligand WA present in both structures. WA slides down to acquire a more structurally stable
configuration by anchoring its tail inside the gorge of HSV POL.
Table 2 Comparison of different parameters of docking
of withaferin A onto DNA POL in pre- and post- MD
simulated structures
Status Pre-MD Post-MD
Binding energy -8.84 Kcal/mol -11.45 Kcal/mol
H-Bond donors 20 23
H-bond acceptors 16 17
log P 48.47 24.84
Molar refractivity 535.3 295.09
ln (Vol) 8.15 8.08
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tor of HSV POL whose binding would result in a confor-
mational change in the polymerase that distorts the
positioning of the residues that bind DNA, inhibiting
polymerization. 4-oxo-DHQs have shown high specificity
index in inhibiting DNA polymerases belonging to the
herpesviridae family because unrelated DNA and RNA
viruses were not susceptible to their inhibitory effect, and
they also proved to have broad spectrum antiviral effects
[35,36]. The same can be expected for WA owing to its
analogous mode of action. The inhibition constant of
WA found in our study (0.6 µm) was also quite compar-
able to the currently established nucleosidic drugs (0.1-
0.6 µm) [37].
The emergence of HSV resistance to antiviral drugs is
also a major concern. Three basic mechanisms have been
identified: altered thymidine kinase substrate specificity,
absent or partial production of viral thymidine kinase
and altered viral DNA polymerase [10]. The most com-
mon mechanism found in clinical isolates is deficient TK
activity. For the foremost approved drug- Acyclovir,
resistant isolates of HSV have been observed in immuno-
compromised individuals, especially AIDS patients [37].
Since WA is observed exerting its inhibitory effect via
interaction with a viral DNA polymerase site that is less
important for the binding of deoxynucleoside tripho-
sphates, it holds potential to exert its influence even on
these resistant isolates. The non-nucleosidic mode of
action of WA holds promise for prevention of infection,
as it can selectively target only the viral enzymes. More-
over being a naturally occurring herbal drug candidate,
WA will also be able to address the issue of safety and
bioavailability.
Based on the results from WA-HSV POL complex, it
appears that interactions with the residues Gln 617, Gln
618, Tyr 722, Asn 815 and Asp 888 of HSV POL are
important for inhibitory activity of WA. A comparison
between the conformation obtained from docking and
that from molecular dynamics simulations show that sub-
stantial changes in binding conformations have occurred.
These results indicate that the initial receptor-ligand inter-
action observed after docking can be limited due to the
receptor rigid docking algorithm and that the conforma-
tions and interactions observed after simulation runs are
more energetically favoured and should be better repre-
sentations of derivative poses in receptor.
Conclusions
We have performed docking and molecular dynamics
simulation studies to elucidate the binding mechanism of
prospective herbal drug withaferin A onto the structure
of DNA polymerase of Herpes simplex virus. Our dock-
ing simulations results give high binding affinity of the
ligand to the receptor. Long de novo MD simulations for
10 ns performed allowed us to evaluate the dynamic
behaviour of the system studied and corroborate the
docking results, as well as identify key residues in the
enzyme-inhibitor interactions. The present MD simula-
t i o n ss u p p o r tt h eh y p o t h e s i st h a tW Ai sap r o s p e c t i v e
ligand that has potential to target/inhibit DNA polymer-
ase of the Herpes simplex virus. Results of these studies
will also guide the design of selective inhibitors of DNA
POL with high specificity and potent activity in order to
strengthen the therapeutic arsenal available today against
the dangerous biological warfare agent represented by
Herpes Simplex Virus.
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